California-based AI firm Suki has raised $70 million in new funding, led by Hedosophia, bringing its total to $165 million.

Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...

Switzerland-based KeyBioscience and US pharma major Eli Lilly have extended their collaboration on dual amylin calcitonin ...

Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in ...

The UK's MHRA has approved Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty (KP.2), for use in adults. This approval ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of ...

Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), ...